Newsroom

Here you will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.

Media Enquiries - CSL Limited
Jemimah Pentland
Head of Communications, Asia Pacific
Phone: +613 9389 3473
Mobile: +61 412 635 483
jemimah.pentland@csl.com.au

RSS Subscribe to our RSS feed

15/02/2017
Half Year Result 20171
Half Year Results Announcement 2017 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP).
 
More.

10/02/2017
Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
Study Published in Cell Metabolism

Melbourne, 10 February, 2017 04.00AM AEDT: An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes. The findings, which are published today in Cell Metabolism, are an important breakthrough in the field of diabetes research.p>

 
More.

19/01/2017
FY2017 profit upgrade
FY2017 profit upgrade CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, particularly by immunoglobulins and specialty products in the most recent financial quarter, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016.
 
More.

05/01/2017
Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
Momenta

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017.

 
More.

>> Prior Archived Newsroom


 

© 2017 CSL Limited